Journal article
RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival
Molecular and cellular biology, Vol.35(19), pp.3324-3338
10/2015
DOI: 10.1128/MCB.00692-15
PMCID: PMC4561725
PMID: 26195820
Abstract
Although TRAIL is considered a potential anticancer agent, it enhances tumor progression by activating NF-κB in apoptosis-resistant cells. Cellular FLICE-like inhibitory protein (cFLIP) overexpression and caspase-8 activation have been implicated in TRAIL-induced NF-κB activation; however, the underlying mechanisms are unknown. Here, we report that caspase-8-dependent cleavage of RIP1 in the kinase domain (KD) and intermediate domain (ID) determines the activation state of the NF-κB pathway in response to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) treatment. In apoptosis-sensitive cells, caspase-8 cleaves RIP1 in the KD and ID immediately after the recruitment of RIP1 to the receptor complex, impairing IκB kinase (IKK) recruitment and NF-κB activation. In apoptosis-resistant cells, cFLIP restricts caspase-8 activity, resulting in limited RIP1 cleavage and generation of a KD-cleaved fragment capable of activating NF-κB but not apoptosis. Notably, depletion of the cytoplasmic pool of TRAF2 and cIAP1 in lymphomas by CD40 ligation inhibits basal RIP1 ubiquitination but does not prompt cell death, due to CD40L-induced cFLIP expression and limited RIP1 cleavage. Inhibition of RIP1 cleavage at the KD suppresses NF-κB activation and cell survival even in cFLIP-overexpressing lymphomas. Importantly, RIP1 is constitutively cleaved in human and mouse lymphomas, suggesting that cFLIP-mediated and caspase-8-dependent limited cleavage of RIP1 is a new layer of mechanism that promotes NF-κB activation and lymphoma survival.
Details
- Title: Subtitle
- RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival
- Creators
- Laiqun Zhang - Department of Pathology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USAKen Blackwell - Department of Pathology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USALauren M Workman - Interdisciplinary Graduate Program in Molecular and Cellular Biology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USASonghai Chen - Department of Pharmacology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USAMarshall R Pope - Proteomic Facility, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USASiegfried Janz - Department of Pathology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USAHasem Habelhah - Department of Pathology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA hasem-habelhah@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Molecular and cellular biology, Vol.35(19), pp.3324-3338
- DOI
- 10.1128/MCB.00692-15
- PMID
- 26195820
- PMCID
- PMC4561725
- NLM abbreviation
- Mol Cell Biol
- ISSN
- 0270-7306
- eISSN
- 1098-5549
- Publisher
- United States
- Grant note
- CA138475 / NCI NIH HHS R01 CA151354 / NCI NIH HHS CA151354 / NCI NIH HHS P30 CA086862 / NCI NIH HHS R01 CA138475 / NCI NIH HHS
- Language
- English
- Date published
- 10/2015
- Academic Unit
- Pathology; Iowa Neuroscience Institute; Fraternal Order of Eagles Diabetes Research Center; Neuroscience and Pharmacology; Medicine Administration; Internal Medicine
- Record Identifier
- 9984040399602771
Metrics
17 Record Views